Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Jobs — and national identity — top French concerns over the news that pharmaceutical company Sanofi plans to sell 50% of ...

Located in midtown Manhattan and designed by SHoP Architects, the 1,428-foot-high skyscraper is the second tallest ...

The key to Sanofi becoming a pure biopharma player: investment. A year later, the French company announced the divestment of ...

Adults in their 30s are at risk of developing metabolic-associated fatty liver disease (MAFLD) due to metabolic changes in ...

You need to be a subscriber to view this content.

Any deal would follow Sanofi’s agreement to sell a controlling stake in its consumer health unit to Clayton Dubilier & Rice in a transaction valuing the Opella unit at about €16 billion. Bain and ...

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Opella Healthcare Participations BV The Exchange has ...